{
  "meta": {
    "title": "Bleeding_Disorders_2_-_Platelet_Function_Disorders",
    "url": "https://brainandscalpel.vercel.app/bleeding-disorders-2-platelet-function-disorders-4c9de074.html",
    "scrapedAt": "2025-11-29T18:24:53.975Z"
  },
  "questions": [
    {
      "id": 20898,
      "choices": [
        {
          "id": 83556,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thromboxane A2 (TxA2) </span></span></span></p>"
        },
        {
          "id": 83557,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adenosine Diphosphate (ADP) </span></span></span></p>"
        },
        {
          "id": 83558,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thrombin</span></span></span></p>"
        },
        {
          "id": 83559,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fibrinogen</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is the PRIMARY agonist responsible for platelet aggregation?</span></span></span></p>",
      "unique_key": "Q8814742",
      "question_audio": null,
      "question_video": null,
      "map_id": 20849,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Fibrinogen</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fibrinogen acts as a bridge between activated GP IIb/IIIa receptors on adjacent platelets, leading to platelet aggregation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Thromboxane A2 (TxA2)</span></strong><span style=\"font-size:12.0pt\">: TxA2 is a potent platelet activator and vasoconstrictor, but it does not directly mediate platelet aggregation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Adenosine Diphosphate (ADP)</span></strong><span style=\"font-size:12.0pt\">: ADP is a weak platelet activator that promotes platelet aggregation by binding to P2Y12 and P2Y1 receptors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Thrombin</span></strong><span style=\"font-size:12.0pt\">: Thrombin is a powerful platelet activator and promotes aggregation through protease-activated receptors (PARs).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fibrinogen is the primary agonist responsible for platelet aggregation by cross-linking activated platelets through GP IIb/IIIa receptors.</span></span></span></p>",
      "correct_choice_id": 83559,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20899,
      "choices": [
        {
          "id": 83560,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin </span></span></span></p>"
        },
        {
          "id": 83561,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel </span></span></span></p>"
        },
        {
          "id": 83562,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Abciximab </span></span></span></p>"
        },
        {
          "id": 83563,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eptifibatide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs inhibits platelet aggregation by irreversibly blocking the P2Y12 receptor?</span></span></p>",
      "unique_key": "Q5039629",
      "question_audio": null,
      "question_video": null,
      "map_id": 20850,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Clopidogrel</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel is an antiplatelet drug that irreversibly inhibits the P2Y12 receptor, thereby preventing ADP-induced platelet activation and aggregation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Aspirin</span></strong><span style=\"font-size:12.0pt\">: Aspirin irreversibly inhibits cyclooxygenase (COX)-1, preventing TxA2 production.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>Abciximab</strong>: Abciximab is a monoclonal antibody that blocks GP IIb/IIIa receptors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Eptifibatide</span></strong><span style=\"font-size:12.0pt\">: Eptifibatide is a cyclic heptapeptide that reversibly blocks GP IIb/IIIa receptors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel inhibits platelet aggregation by irreversibly blocking the P2Y12 receptor.</span></span></span></p>",
      "correct_choice_id": 83561,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20900,
      "choices": [
        {
          "id": 83564,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Von Willebrand Disease (VWD) </span></span></span></p>"
        },
        {
          "id": 83565,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemophilia A </span></span></span></p>"
        },
        {
          "id": 83566,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glanzmann thrombasthenia </span></span></span></p>"
        },
        {
          "id": 83567,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immune Thrombocytopenia Purpura (ITP)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old boy presents with a history of easy bruising, frequent nosebleeds, and prolonged bleeding after minor injuries. His parents report that he had significant bleeding during circumcision as a newborn. Platelet count and coagulation studies are normal. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q9247800",
      "question_audio": null,
      "question_video": null,
      "map_id": 20851,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Glanzmann thrombasthenia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glanzmann thrombasthenia is a rare inherited platelet disorder characterized by defective platelet aggregation due to a deficiency or dysfunction of the glycoprotein (GP) IIb/IIIa complex. This leads to a lifelong bleeding diathesis, typically presenting with mucocutaneous bleeding (e.g., epistaxis, gingival bleeding, petechiae, purpura) and prolonged bleeding after trauma or surgery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Von Willebrand Disease (VWD):</span></strong><span style=\"font-size:12.0pt\"> VWD is the most common inherited bleeding disorder caused by a deficiency or defect in von Willebrand factor (vWF). While it can present with mucocutaneous bleeding, it is usually associated with prolonged bleeding time and abnormal platelet function tests (e.g., ristocetin cofactor activity).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hemophilia A:</span></strong><span style=\"font-size:12.0pt\"> Hemophilia A is an X-linked recessive disorder caused by a deficiency of factor VIII. It typically presents with deep tissue bleeding (e.g., hemarthrosis) rather than mucocutaneous bleeding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Immune Thrombocytopenia Purpura (ITP):</span></strong><span style=\"font-size:12.0pt\"> ITP is an autoimmune disorder characterized by isolated thrombocytopenia due to increased platelet destruction. It is not typically associated with a history of significant bleeding in the neonatal period.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glanzmann thrombasthenia is a rare but important differential diagnosis in patients presenting with a history of mucocutaneous bleeding and normal platelet count and coagulation studies. A platelet aggregation test can confirm the diagnosis.</span></span></span></p>",
      "correct_choice_id": 83566,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20902,
      "choices": [
        {
          "id": 83572,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ristocetin cofactor activity </span></span></span></p>"
        },
        {
          "id": 83573,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platelet aggregation studies </span></span></span></p>"
        },
        {
          "id": 83574,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor VIII assay </span></span></span></p>"
        },
        {
          "id": 83575,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bone marrow biopsy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old female presents with a history of heavy menstrual bleeding since menarche. She also reports easy bruising and prolonged bleeding after minor cuts. Physical examination reveals scattered petechiae. Which of the following tests is most likely to be diagnostic?</span></span></p>",
      "unique_key": "Q3344899",
      "question_audio": null,
      "question_video": null,
      "map_id": 20852,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Platelet aggregation studies</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platelet aggregation studies are the most specific test for diagnosing Glanzmann thrombasthenia, a likely diagnosis based on the patient&#39;s history and physical examination. They will show absent or markedly reduced aggregation in response to multiple agonists.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ristocetin cofactor activity</span></strong><span style=\"font-size:12.0pt\">: This test measures the function of von Willebrand factor (vWF) and is used in the diagnosis of von Willebrand disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Factor VIII assay</span></strong><span style=\"font-size:12.0pt\">: This test is used to diagnose hemophilia A.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Bone marrow biopsy</span></strong><span style=\"font-size:12.0pt\">: This test is not indicated in the initial workup of suspected Glanzmann thrombasthenia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platelet aggregation studies are the definitive test for diagnosing Glanzmann thrombasthenia.</span></span></span></p>",
      "correct_choice_id": 83573,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20903,
      "choices": [
        {
          "id": 83576,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Von Willebrand Disease (VWD) </span></span></span></p>"
        },
        {
          "id": 83577,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemophilia A </span></span></span></p>"
        },
        {
          "id": 83578,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glanzmann thrombasthenia </span></span></span></p>"
        },
        {
          "id": 83579,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bernard-Soulier syndrome (BSS)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 4-year-old child presents with a history of easy bruising, frequent epistaxis, and heavy menstrual bleeding (in females). Peripheral blood smear shows giant platelets. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q9283973",
      "question_audio": null,
      "question_video": null,
      "map_id": 20853,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Bernard-Soulier syndrome (BSS)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BSS is characterized by giant platelets and thrombocytopenia. It is a rare inherited disorder of platelet adhesion due to a deficiency of the glycoprotein Ib-IX-V complex.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Von Willebrand Disease (VWD)</span></strong><span style=\"font-size:12.0pt\">: VWD presents with mucocutaneous bleeding and prolonged bleeding time, but not giant platelets.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hemophilia A</span></strong><span style=\"font-size:12.0pt\">: Hemophilia A is characterized by a deficiency of factor VIII and typically presents with deep tissue bleeding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Glanzmann thrombasthenia</span></strong><span style=\"font-size:12.0pt\">: Glanzmann thrombasthenia is a platelet aggregation disorder and does not cause giant platelets.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Giant platelets on peripheral blood smear are a hallmark of Bernard-Soulier syndrome.</span></span></span></p>",
      "correct_choice_id": 83579,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20904,
      "choices": [
        {
          "id": 83580,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thrombocytopenia </span></span></span></p>"
        },
        {
          "id": 83581,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Giant platelets on peripheral smear</span></span></span></p>"
        },
        {
          "id": 83582,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prolonged bleeding time </span></span></span></p>"
        },
        {
          "id": 83583,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal ristocetin cofactor activity</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following laboratory findings is NOT characteristic of Bernard-Soulier syndrome (BSS)?</span></span></p>",
      "unique_key": "Q5187880",
      "question_audio": null,
      "question_video": null,
      "map_id": 20854,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Normal ristocetin cofactor activity</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ristocetin cofactor activity (vWF-dependent platelet agglutination) is typically decreased in BSS due to the defective interaction between platelets and vWF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased ristocetin cofactor activity is a characteristic finding in BSS, helping to differentiate it from other platelet disorders.</span></span></span></p>",
      "correct_choice_id": 83583,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20905,
      "choices": [
        {
          "id": 83584,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Giant platelets </span></span></span></p>"
        },
        {
          "id": 83585,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Absence of dense granules </span></span></span></p>"
        },
        {
          "id": 83586,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Absence of alpha granules </span></span></span></p>"
        },
        {
          "id": 83587,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Abnormal platelet aggregation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 3-year-old child presents with a history of easy bruising, frequent nosebleeds, and prolonged bleeding after minor injuries. The platelet count is normal, but the peripheral blood smear reveals large platelets, Ultrasound imaging showed Mild spleenomegaly. Given the likely diagnosis, Which of the following is the most characteristic electron microscopy finding in Gray platelet syndrome?</span></span></p>",
      "unique_key": "Q4512407",
      "question_audio": null,
      "question_video": null,
      "map_id": 20855,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Absence of alpha granules</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The defining feature of Gray platelet syndrome is the absence of alpha granules in platelets on electron microscopy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Giant platelets</span></strong><span style=\"font-size:12.0pt\">: While platelets may be large on peripheral smear, giant platelets are more characteristic of Bernard-Soulier syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Absence of dense granules</span></strong><span style=\"font-size:12.0pt\">: This is a feature of other platelet disorders, not Gray platelet syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Abnormal platelet aggregation</span></strong><span style=\"font-size:12.0pt\">: Platelet aggregation is variable in Gray platelet syndrome but is not the most specific finding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The absence of alpha granules on electron microscopy is the hallmark of Gray platelet syndrome.</span></span></span></p>",
      "correct_choice_id": 83586,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20906,
      "choices": [
        {
          "id": 83588,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HPS1 </span></span></span></p>"
        },
        {
          "id": 83589,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HPS3 </span></span></span></p>"
        },
        {
          "id": 83590,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HPS5 </span></span></span></p>"
        },
        {
          "id": 83591,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NBEAL2</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old child presents with oculocutaneous albinism, recurrent bacterial infections, and easy bruising. Peripheral smear shows normal platelet count but abnormal granulation. On further evaluation, Platelet EM studies show&nbsp;</span></span><span dir=\"ltr\" lang=\"EL\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&delta; </span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">granule deficiency. The treating physician is suspecting a platelet disorder,&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following genetic mutations is NOT associated with the likely diagnosis?</span></span></p>",
      "unique_key": "Q7024653",
      "question_audio": null,
      "question_video": null,
      "map_id": 20856,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) NBEAL2</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NBEAL2 gene mutation is associated with Gray platelet syndrome, not <strong>Hermansky Pudlak Syndrome. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HPS is caused by mutations in several genes, including HPS1, HPS3, and HPS5.</span></span></span></p>",
      "correct_choice_id": 83591,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52815,
      "choices": [
        {
          "id": 210749,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Staphylococcus aureus </span></span></span></p>"
        },
        {
          "id": 210750,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Streptococcus pneumoniae </span></span></span></p>"
        },
        {
          "id": 210751,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pseudomonas aeruginosa </span></span></span></p>"
        },
        {
          "id": 210752,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Candida albicans</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 4-year-old child presents with recurrent pyogenic skin and respiratory infections, silver-grey hair, and nystagmus. Peripheral blood smear reveals giant granules in neutrophils. Given the likely diagnosis, Which of the following infections is MOST frequently associated with this condition?</span></span></p>",
      "unique_key": "Q7455136",
      "question_audio": null,
      "question_video": null,
      "map_id": 25151,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Staphylococcus aureus</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with Chediak-Higashi syndrome are particularly susceptible to Staphylococcus aureus infections due to impaired neutrophil function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Streptococcus pneumoniae:</span></strong><span style=\"font-size:12.0pt\"> While patients with Chediak-Higashi syndrome may be more susceptible to infections in general, there isn&#39;t a specific predisposition towards Streptococcus pneumoniae compared to Staphylococcus aureus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pseudomonas aeruginosa:</span></strong><span style=\"font-size:12.0pt\"> Pseudomonas is more commonly associated with patients with cystic fibrosis or other immunocompromised states. It&#39;s not a hallmark infection for Chediak-Higashi.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Candida albicans:</span></strong><span style=\"font-size:12.0pt\"> This is a fungal infection, and while Chediak-Higashi syndrome patients may be more susceptible to infections overall, bacterial infections (especially those caused by Staphylococcus aureus) are of greater concern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recurrent Staphylococcus aureus infections are a hallmark of Chediak-Higashi syndrome.</span></span></span></p>",
      "correct_choice_id": 210749,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52816,
      "choices": [
        {
          "id": 210753,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">LYST </span></span></span></p>"
        },
        {
          "id": 210754,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CHS1 </span></span></span></p>"
        },
        {
          "id": 210755,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NBEAL2 </span></span></span></p>"
        },
        {
          "id": 210756,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HPS1</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following gene mutations is responsible for Chediak-Higashi syndrome?</span></span></p>",
      "unique_key": "Q5459177",
      "question_audio": null,
      "question_video": null,
      "map_id": 25152,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans B) CHS1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mutations in the CHS1 (LYST) gene are responsible for Chediak-Higashi syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. LYST:</span></strong><span style=\"font-size:12.0pt\"> While historically known as LYST, the official gene symbol is now CHS1. Both refer to the same gene, so this is not technically incorrect, but B) is the preferred answer due to the updated nomenclature.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. NBEAL2:</span></strong><span style=\"font-size:12.0pt\"> Mutations in the NBEAL2 gene cause Gray Platelet Syndrome (GPS), a distinct disorder with large platelets and bleeding tendency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. HPS1:</span></strong><span style=\"font-size:12.0pt\"> Mutations in the HPS1 gene cause a subtype of Hermansky-Pudlak Syndrome (HPS), another disorder with albinism, but with a different pattern of organ involvement than Chediak-Higashi syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mutations in the CHS1 gene lead to defective lysosomal trafficking, resulting in the characteristic giant granules and impaired immune function in Chediak-Higashi syndrome.</span></span></span></p>",
      "correct_choice_id": 210754,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52817,
      "choices": [
        {
          "id": 210757,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemophilia A </span></span></span></p>"
        },
        {
          "id": 210758,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemophilia B </span></span></span></p>"
        },
        {
          "id": 210759,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Von Willebrand Disease (VWD) Type 1 </span></span></span></p>"
        },
        {
          "id": 210760,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Von Willebrand Disease (VWD) Type 3</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old woman presents with easy bruising, heavy menstrual bleeding, and prolonged bleeding after minor cuts. Her family history reveals similar bleeding tendencies in her mother and sister. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q4515178",
      "question_audio": null,
      "question_video": null,
      "map_id": 25153,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Von Willebrand Disease (VWD) Type 1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">VWD Type 1 is the most common inherited bleeding disorder, characterized by a partial quantitative deficiency of von Willebrand factor (vWF). This leads to impaired platelet adhesion and a mild-to-moderate bleeding tendency. The family history supports an inherited bleeding disorder.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option </span></strong><strong><span style=\"font-size:12.0pt\">A. Hemophilia A </span></strong><span style=\"font-size:12.0pt\">and </span><strong><span style=\"font-size:12.0pt\">Option B. Hemophilia B:</span></strong><span style=\"font-size:12.0pt\"> These are X-linked recessive disorders primarily affecting males and are characterized by factor VIII and IX deficiencies, respectively.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Von Willebrand Disease (VWD) Type 3</span></strong><span style=\"font-size:12.0pt\">: This is a rare, severe form of VWD with almost complete absence of vWF, usually presenting with more severe bleeding symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">VWD Type 1 is the most common inherited bleeding disorder and often presents with mucocutaneous bleeding and a positive family history.</span></span></span></p>",
      "correct_choice_id": 210759,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52818,
      "choices": [
        {
          "id": 210761,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Von Willebrand disease (VWD) type 1 </span></span></span></p>"
        },
        {
          "id": 210762,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Von Willebrand disease (VWD) type 2 </span></span></span></p>"
        },
        {
          "id": 210763,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Von Willebrand disease (VWD) type 3 </span></span></span></p>"
        },
        {
          "id": 210764,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acquired von Willebrand syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old man with a history of easy bruising and prolonged bleeding after minor procedures undergoes laboratory testing. The results reveal a normal von Willebrand factor (vWF) antigen level, but a decreased vWF ristocetin cofactor activity (RCoF). Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q3216491",
      "question_audio": null,
      "question_video": null,
      "map_id": 25154,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Von Willebrand disease (VWD) type 2</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This type of VWD is characterized by qualitative defects in vWF. While the quantity of vWF (antigen level) may be normal, its function (RCoF) is impaired, leading to bleeding problems.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Von Willebrand disease (VWD) type 1:</span></strong><span style=\"font-size:12.0pt\"> In VWD type 1, both vWF antigen and RCoF levels are decreased proportionally, not just the RCoF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Von Willebrand disease (VWD) type 3:</span></strong><span style=\"font-size:12.0pt\"> This is the most severe form of VWD with a near-complete absence of vWF, so both antigen and RCoF would be very low.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Acquired von Willebrand syndrome:</span></strong><span style=\"font-size:12.0pt\"> While this can mimic VWD, it is usually associated with underlying conditions like lymphoproliferative disorders, autoimmune diseases, or certain medications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A normal vWF antigen level with a decreased RCoF strongly suggests a qualitative defect in vWF, which is characteristic of VWD type 2. Further testing can determine the specific subtype (2A, 2B, 2M, or 2N).</span></span></span></p>",
      "correct_choice_id": 210762,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52819,
      "choices": [
        {
          "id": 210765,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type 1 VWD </span></span></span></p>"
        },
        {
          "id": 210766,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type 2A VWD </span></span></span></p>"
        },
        {
          "id": 210767,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type 2B VWD </span></span></span></p>"
        },
        {
          "id": 210768,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type 3 VWD</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with a lifelong history of heavy menstrual bleeding and easy bruising. She reports that her father also had similar bleeding issues. Her laboratory results show a normal platelet count, prolonged bleeding time, and reduced von Willebrand factor (vWF) antigen and ristocetin cofactor activity (R:Co). Which type of von Willebrand disease (VWD) is most likely?</span></span></p>",
      "unique_key": "Q7629337",
      "question_audio": null,
      "question_video": null,
      "map_id": 25155,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Type 1 VWD</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type 1 VWD is the most common type and is characterized by a quantitative deficiency of vWF, resulting in reduced vWF antigen, R:Co activity, and factor VIII levels. The patient&#39;s history of lifelong bleeding, normal platelet count, and positive family history support this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Type 2A VWD</span></strong><span style=\"font-size:12.0pt\">: Presents with normal vWF antigen but decreased R:Co activity due to a qualitative defect in vWF multimers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Type 2B VWD</span></strong><span style=\"font-size:12.0pt\">: Presents with thrombocytopenia due to increased vWF-platelet binding, unlike the normal platelet count in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Type 3 VWD</span></strong><span style=\"font-size:12.0pt\">: Presents with severe deficiency of vWF, leading to more severe bleeding than described in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type 1 VWD is the most common type and presents with a quantitative deficiency of vWF, causing mild to moderate bleeding.</span></span></span></p>",
      "correct_choice_id": 210765,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52820,
      "choices": [
        {
          "id": 210769,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type 1 VWD </span></span></span></p>"
        },
        {
          "id": 210770,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type 2A VWD </span></span></span></p>"
        },
        {
          "id": 210771,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type 2M VWD </span></span></span></p>"
        },
        {
          "id": 210772,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type 2N VWD</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 10-year-old boy presents with recurrent nosebleeds and prolonged bleeding after dental procedures. His laboratory results show a normal platelet count, prolonged bleeding time, and normal vWF antigen levels, but markedly reduced FVIII levels. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q4096286",
      "question_audio": null,
      "question_video": null,
      "map_id": 25156,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Type 2N VWD</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This is a subtype of von Willebrand disease (VWD) where there is a qualitative defect in the von Willebrand factor (vWF) molecule, specifically in its ability to bind to factor VIII (FVIII). This leads to reduced FVIII levels in the blood, resulting in symptoms similar to mild hemophilia A. This patient&#39;s presentation with recurrent bleeding, prolonged bleeding time, normal vWF antigen but reduced FVIII levels strongly suggests Type 2N VWD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Type 1 VWD:</span></strong><span style=\"font-size:12.0pt\"> This type has a quantitative deficiency of vWF, so both vWF antigen and activity would be reduced.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Type 2A VWD:</span></strong><span style=\"font-size:12.0pt\"> This type has a qualitative defect leading to decreased high molecular weight multimers of vWF, but FVIII levels are typically normal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Type 2M VWD:</span></strong><span style=\"font-size:12.0pt\"> This type also has a qualitative defect, but it mainly affects platelet adhesion, not FVIII binding. FVIII levels are usually normal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When a patient presents with bleeding symptoms and a prolonged bleeding time, it is important to measure both vWF and FVIII levels to distinguish between VWD and hemophilia. A normal vWF antigen with decreased FVIII is highly suggestive of Type 2N VWD</span></span></span></p>",
      "correct_choice_id": 210772,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52821,
      "choices": [
        {
          "id": 210773,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor VIII concentrate </span></span></span></p>"
        },
        {
          "id": 210774,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recombinant von Willebrand factor (rVWF) concentrate </span></span></span></p>"
        },
        {
          "id": 210775,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Desmopressin (DDAVP) </span></span></span></p>"
        },
        {
          "id": 210776,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cryoprecipitate</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old woman with a history of heavy menstrual bleeding and easy bruising is diagnosed with von Willebrand disease (VWD) type 1. Which of the following is the most appropriate initial treatment for a minor bleeding episode?</span></span></p>",
      "unique_key": "Q5454959",
      "question_audio": null,
      "question_video": null,
      "map_id": 25157,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Desmopressin (DDAVP)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">DDAVP is the first-line treatment for mild to moderate bleeding in VWD type 1 as it stimulates the release of endogenous vWF from endothelial cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Factor VIII concentrate</span></strong><span style=\"font-size:12.0pt\">: Primarily used for hemophilia A, not VWD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. rVWF concentrate</span></strong><span style=\"font-size:12.0pt\">: Reserved for more severe bleeding or VWD types 2 and 3.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cryoprecipitate</span></strong><span style=\"font-size:12.0pt\">: An older treatment option, less preferred due to risk of viral transmission.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">DDAVP is a safe and effective initial treatment for mild bleeding in VWD type 1.</span></span></span></p>",
      "correct_choice_id": 210775,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53085,
      "choices": [
        {
          "id": 211829,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Evasive behavior when asked about the hematomas</span></span></span></p>"
        },
        {
          "id": 211830,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">History of spontaneous hematomas in paternal grandmother</span></span></span></p>"
        },
        {
          "id": 211831,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Petechiae in the oropharynx</span></span></span></p>"
        },
        {
          "id": 211832,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intraarticular iron deposition</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 22-year-old man with a history of frequent nosebleeds and prolonged bleeding after a tooth extraction presents with recurrent, painless bloody urine. Examination reveals multiple hematomas and decreased range of motion with crepitus in both ankles. Laboratory studies show a normal platelet count, prolonged partial thromboplastin time (PTT), and hematuria without RBC casts. An&nbsp;x-ray&nbsp;of the pelvis shows no abnormalities. Further evaluation of this patient is most likely to show which of the following findings?</span></span></p>",
      "unique_key": "Q2758937",
      "question_audio": null,
      "question_video": null,
      "map_id": 25208,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Intraarticular iron deposition</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeated hemarthrosis (bleeding into joints) is a hallmark of hemophilia. This leads to iron deposition within the joint (hemosiderin) due to the breakdown of red blood cells. Over time, this iron can cause synovitis and cartilage damage, resulting in chronic joint problems and a decreased range of motion, as seen in this patient. An MRI or ultrasound would be the best way to confirm this finding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Evasive behavior when asked about the hematomas:</span></strong><span style=\"font-size:12.0pt\"> While this might be present in some cases, it&#39;s not specific to hemophilia and doesn&#39;t help confirm the diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. History of spontaneous hematomas in paternal grandmother:</span></strong><span style=\"font-size:12.0pt\"> While hemophilia is often inherited, a family history alone is not enough to diagnose the condition. Direct testing for factor deficiencies is needed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Petechiae in the oropharynx:</span></strong><span style=\"font-size:12.0pt\"> Petechiae are typically associated with thrombocytopenia (low platelet count), not hemophilia. This patient&#39;s platelet count is normal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In a patient with suspected hemophilia, further evaluation with imaging studies like MRI or ultrasound is essential to assess joint damage and confirm the diagnosis of hemophilic arthropathy. A positive family history can raise suspicion, but definitive diagnosis requires factor assays.</span></span></span></p>",
      "correct_choice_id": 211832,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53088,
      "choices": [
        {
          "id": 211841,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Von Willebrand Disease (VWD) </span></span></span></p>"
        },
        {
          "id": 211842,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin K deficiency </span></span></span></p>"
        },
        {
          "id": 211843,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemophilia A </span></span></span></p>"
        },
        {
          "id": 211844,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Disseminated Intravascular Coagulation (DIC)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 2-year-old boy presents with a swollen and painful right knee after falling from a chair. He has a history of easy bruising and prolonged bleeding after minor injuries. Family history reveals a maternal uncle with a bleeding disorder. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q2207050",
      "question_audio": null,
      "question_video": null,
      "map_id": 25209,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Hemophilia A</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation (hemarthrosis, easy bruising, family history) and age are highly suggestive of hemophilia. Since it&#39;s more common and typically X-linked recessive (maternal uncle affected), Hemophilia A is the most likely diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Von Willebrand Disease (VWD):&nbsp;</span></strong><span style=\"font-size:12.0pt\">While it can cause bleeding, hemarthrosis is less common and the family history points more towards hemophilia<strong>.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Vitamin K deficiency:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This would cause bleeding due to impaired clotting factor synthesis, but it&#39;s less common in young children with no dietary restrictions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Disseminated Intravascular Coagulation (DIC):&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is a life-threatening condition with widespread clotting and bleeding, not just isolated hemarthrosis<strong>.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemarthrosis in young boys with a family history of bleeding disorders should raise suspicion for hemophilia A.</span></span></span></p>",
      "correct_choice_id": 211843,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53089,
      "choices": [
        {
          "id": 211845,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-compliance with therapy </span></span></span></p>"
        },
        {
          "id": 211846,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Development of an inhibitor against factor VIII </span></span></span></p>"
        },
        {
          "id": 211847,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inadequate dose of factor VIII </span></span></span></p>"
        },
        {
          "id": 211848,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor VIII product contamination</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 10-year-old boy with severe hemophilia A has been receiving regular factor VIII replacement therapy. He presents with a hemarthrosis despite receiving his usual prophylactic dose. Which of the following is the most likely explanation?</span></span></p>",
      "unique_key": "Q3158716",
      "question_audio": null,
      "question_video": null,
      "map_id": 25210,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Development of an inhibitor against factor VIII</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The development of inhibitors against factor VIII is a major complication of hemophilia treatment, especially in patients with severe disease. Inhibitors can neutralize the infused factor, rendering it ineffective.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Non-compliance with therapy</span></strong><span style=\"font-size:12.0pt\">: Non-compliance is less likely in a patient receiving regular prophylaxis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inadequate dose of factor VIII</span></strong><span style=\"font-size:12.0pt\">: Inadequate dose would not explain the failure of the usual dose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Factor VIII product contamination</span></strong><span style=\"font-size:12.0pt\">: Contamination is a rare occurrence.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objectives</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Suspect inhibitor development in hemophilia patients who fail to respond to their usual factor replacement dose.</span></span></span></p>",
      "correct_choice_id": 211846,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53091,
      "choices": [
        {
          "id": 211853,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immediate administration of factor VIII concentrate </span></span></span></p>"
        },
        {
          "id": 211854,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Emergency endoscopy to identify the bleeding source </span></span></span></p>"
        },
        {
          "id": 211855,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Urgent CT scan of the abdomen </span></span></span></p>"
        },
        {
          "id": 211856,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Admission to the ICU for monitoring</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 15-year-old boy with severe hemophilia A presents with sudden onset of abdominal pain and hematemesis. Which of the following is the most appropriate initial management?</span></span></span></p>",
      "unique_key": "Q1044256",
      "question_audio": null,
      "question_video": null,
      "map_id": 25211,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Immediate administration of factor VIII concentrate</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In a hemophiliac with severe bleeding, prompt factor replacement is crucial to control hemorrhage and prevent further complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Emergency endoscopy to identify the bleeding source</span></strong><span style=\"font-size:12.0pt\">: Endoscopy can be helpful, but immediate factor replacement is a priority.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Urgent CT scan of the abdomen</span></strong><span style=\"font-size:12.0pt\">: CT scan might be needed later, but not the most urgent step.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Admission to the ICU for monitoring</span></strong><span style=\"font-size:12.0pt\">: ICU admission might be necessary depending on the severity, but factor replacement comes first.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prioritize immediate factor replacement in hemophilia patients with severe bleeding episodes.</span></span></span></p>",
      "correct_choice_id": 211853,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53093,
      "choices": [
        {
          "id": 211861,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor VIII only </span></span></span></p>"
        },
        {
          "id": 211862,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor IX only </span></span></span></p>"
        },
        {
          "id": 211863,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Both Factor VIII and von Willebrand Factor (vWF) </span></span></span></p>"
        },
        {
          "id": 211864,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor VIII, vWF, and Factor IX</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following coagulation factors are increased by the administration of DDAVP?</span></span></p>",
      "unique_key": "Q8417043",
      "question_audio": null,
      "question_video": null,
      "map_id": 25212,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Both Factor VIII and von Willebrand Factor (vWF)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Desmopressin (DDAVP) acts by stimulating the release of both Factor VIII and von Willebrand factor (vWF) from storage sites within endothelial cells. This leads to a temporary increase in their levels in the blood, aiding in clot formation and controlling bleeding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Factor VIII only</span></strong><span style=\"font-size:12.0pt\">: While DDAVP does increase Factor VIII, it also increases vWF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Factor IX only</span></strong><span style=\"font-size:12.0pt\">: DDAVP does not affect Factor IX levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Factor VIII, vWF, and Factor IX</span></strong><span style=\"font-size:12.0pt\">: This is incorrect because, as mentioned above, DDAVP does not affect Factor IX levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">DDAVP is a useful therapeutic agent in certain bleeding disorders, particularly mild hemophilia A and some types of von Willebrand disease (VWD), due to its ability to increase the levels of both Factor VIII and vWF. Understanding its mechanism of action is crucial for selecting appropriate patients for treatment and anticipating its effects.</span></span></span></p>",
      "correct_choice_id": 211863,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53095,
      "choices": [
        {
          "id": 211869,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute pancreatitis </span></span></span></p>"
        },
        {
          "id": 211870,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bacterial sepsis </span></span></span></p>"
        },
        {
          "id": 211871,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Malignant hypertension </span></span></span></p>"
        },
        {
          "id": 211872,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thrombotic thrombocytopenic purpura (TTP)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old male presents with a high fever, hypotension, and altered mental status. He has been experiencing abdominal pain and diarrhea for the past 24 hours. Laboratory investigations reveal prolonged prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombocytopenia. Which of the following is the most likely cause of his condition?</span></span></p>",
      "unique_key": "Q6747185",
      "question_audio": null,
      "question_video": null,
      "map_id": 25213,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Bacterial sepsis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s clinical presentation of fever, hypotension, altered mental status, and laboratory findings (prolonged PT/aPTT, thrombocytopenia) are consistent with disseminated intravascular coagulation (DIC). The most common cause of DIC is sepsis, and given the patient&#39;s history of abdominal pain and diarrhea, bacterial sepsis is the most likely etiology.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Acute pancreatitis</span></strong><span style=\"font-size:12.0pt\">: While pancreatitis can trigger DIC, it is less common than sepsis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Malignant hypertension</span></strong><span style=\"font-size:12.0pt\">: Malignant hypertension can cause thrombotic microangiopathy but not typically DIC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Thrombotic thrombocytopenic purpura (TTP): </span></strong><span style=\"font-size:12.0pt\">TTP is a distinct disorder characterized by ADAMTS13 deficiency and does not typically present with prolonged PT/aPTT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sepsis is the most common cause of disseminated intravascular coagulation (DIC), and the clinical presentation often includes signs of systemic infection and abnormal coagulation parameters.</span></span></span></p>",
      "correct_choice_id": 211870,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53096,
      "choices": [
        {
          "id": 211873,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor VIII gene mutation </span></span></span></p>"
        },
        {
          "id": 211874,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor V gene mutation </span></span></span></p>"
        },
        {
          "id": 211875,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">LMAN1 gene mutation </span></span></span></p>"
        },
        {
          "id": 211876,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prothrombin gene mutation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old male presents with a history of mild bleeding tendencies since childhood, primarily after trauma or surgery. He is found to have prolonged PT and aPTT, both of which correct with mixing studies. Which of the following genetic mutations is most likely associated with his condition?</span></span></p>",
      "unique_key": "Q6084461",
      "question_audio": null,
      "question_video": null,
      "map_id": 25214,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) LMAN1 gene mutation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation and laboratory findings are consistent with combined factor V and factor VIII deficiency, a rare autosomal recessive disorder caused by mutations in the LMAN1 gene.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Factor VIII gene mutation</span></strong><span style=\"font-size:12.0pt\">: Causes hemophilia A, with isolated prolongation of aPTT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Factor V gene mutation</span></strong><span style=\"font-size:12.0pt\">: Causes factor V deficiency, with isolated prolongation of PT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prothrombin gene mutation</span></strong><span style=\"font-size:12.0pt\">: Causes prothrombin deficiency, with isolated prolongation of PT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Combined factor V and factor VIII deficiency is associated with mutations in the LMAN1 gene, leading to mild bleeding tendencies.</span></span></span></p>",
      "correct_choice_id": 211875,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}